Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12-15, 2026. The presentation is scheduled for 2:15–2:55 p.m. PT on Monday, January 12, 2026. Dr. Lian will also participate in one-on-one meetings. A live webcast will be accessible from Viking Therapeutics' Investors & Media Webcasts page, and a replay will be posted after the conference.
Positive
- None.
Negative
- None.
News Market Reaction 74 Alerts
On the day this news was published, VKTX gained 0.50%, reflecting a mild positive market reaction. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 74 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $3.84B at that time. Trading volume was elevated at 2.6x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Down
Momentum scanner shows CRNX moving -5.460000038146973% on no same-day news flag there, while other close peers show mixed moves. Several peers (XENE, SRRK) also issued J.P. Morgan conference appearance news, indicating a sector-wide conference theme rather than a unified price direction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Phase 3 enrollment | Positive | -4.6% | Completion of Phase 3 VANQUISH-1 enrollment ahead of schedule and above target. |
| Nov 06 | Clinical data update | Positive | +2.2% | Phase 2 VENTURE obesity data showing strong metabolic and weight-loss outcomes. |
| Nov 04 | Investor conferences | Positive | +5.3% | Participation in Stifel and Jefferies healthcare investor conferences with presentations and meetings. |
| Oct 29 | Conference presentations | Positive | +0.8% | Planned VK2735 obesity data and study design presentations at ObesityWeek and AHA. |
| Oct 22 | Earnings and update | Negative | -4.7% | Q3 2025 results with higher R&D spend, wider loss, and program updates. |
VKTX news on clinical progress and conference participation has often seen price alignment, while at least one clearly positive Phase 3 milestone coincided with a short-term negative reaction.
Over the past few months, Viking reported several key milestones. On Oct 22, 2025, Q3 results highlighted a $715 million cash position and advancing VK2735 programs. Subsequent October and November releases focused on VK2735 obesity clinical data and Phase 3 VANQUISH study designs, plus presentations at ObesityWeek® and AHA, generally accompanied by modest positive price reactions. The Nov 19, 2025 announcement of completing Phase 3 VANQUISH-1 enrollment ahead of schedule saw a -4.56% move, contrasting with the otherwise supportive backdrop as the company continues active investor outreach.
Market Pulse Summary
This announcement highlights Viking’s participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12–15, 2026, with a scheduled corporate presentation and 1‑on‑1 meetings. It continues an active investor-relations cadence following recent obesity program updates and financial disclosures. Investors monitoring this name may focus on how management frames VK2735’s Phase 3 progress, cash deployment, and upcoming 2026 milestones during the presentation and webcast replay.
AI-generated analysis. Not financial advice.
Details are as follows:
- 44th Annual J.P. Morgan Healthcare Conference
Details: Dr. Lian will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Dates: January 12-15, 2026
Presentation Timing: 2:15 – 2:55 p.m. Pacific on Monday, January 12, 2026
Location:San Francisco, California ; webcast available
A live webcast of the presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302652864.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) present at the J.P. Morgan Healthcare Conference in 2026?
Who is presenting for Viking Therapeutics (VKTX) at the January 2026 J.P. Morgan conference?
How can investors watch Viking Therapeutics (VKTX) presentation at the J.P. Morgan conference?
What are the J.P. Morgan Healthcare Conference dates for Viking Therapeutics (VKTX)?
Will Viking Therapeutics (VKTX) hold meetings at the 2026 J.P. Morgan Healthcare Conference?
Where will the Viking Therapeutics (VKTX) J.P. Morgan presentation take place?
